In:
Dementia and Geriatric Cognitive Disorders Extra, S. Karger AG, Vol. 4, No. 3 ( 2014-11-15), p. 450-456
Abstract:
〈 b 〉 〈 i 〉 Background/Aim: 〈 /i 〉 〈 /b 〉 Recent data have indicated that the rs1080985 single nucleotide polymorphism (SNP) of the 〈 i 〉 cytochrome P450 (CYP) 2D6 〈 /i 〉 and the common 〈 i 〉 apolipoprotein E (APOE) 〈 /i 〉 gene may affect the response to donepezil in patients with Alzheimer's disease (AD). We investigated this association in Chinese patients with mild-to-moderate AD. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 In this prospective cohort study, analyses of CYP2D6 and APOE were conducted in 208 native Chinese patients with mild-to-moderate AD. All patients were treated with donepezil 5 mg/day for 6 months, and the response to treatment was assessed using the Mini-Mental State Examination. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 No significant differences between responders (68.9%) and nonresponders (31.1%) to donepezil treatment (6 months' duration) were observed in the distribution of the 〈 i 〉 CYP2D6 〈 /i 〉 rs1080985 SNP, common 〈 i 〉 APOE 〈 /i 〉 polymorphism or a combination of the two. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Our results suggest that neither the 〈 i 〉 CYP2D6 〈 /i 〉 nor the 〈 i 〉 APOE 〈 /i 〉 polymorphism influences the 6-month response to donepezil treatment in a Chinese population with AD.
Type of Medium:
Online Resource
ISSN:
1664-5464
Language:
English
Publisher:
S. Karger AG
Publication Date:
2014
detail.hit.zdb_id:
2621464-7